The Recall Desk
Agency classClass IOur severity:CriticalFDA (Drugs)·D-1180-2018·Announced 2018-08-29

FDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures

Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.

The agency’s classification

FDA (Drugs): Class I

Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 5/5 (Critical).

Highest-severity recall. The hazard can cause serious injury or death. Stop using the product now and follow the agency's instructions.

Our severity reasoning: The source metadata explicitly identifies this as an FDA Class I recall, which corresponds to a Critical severity score of 5 according to the rubric.

Plain-English summary

The U.S. Food and Drug Administration (FDA) has issued a Class I recall for Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1/2 grain (30 mg), 100-count bottles. The product is manufactured for Westminster Pharmaceuticals, LLC, and is available by prescription only. The recall covers specific lots with expiration dates ranging from August 31, 2019, to March 31, 2020.

The recall was initiated because the product was manufactured using an adulterated active pharmaceutical ingredient. Additionally, a lack of process controls and good manufacturing practices resulted in the finished product failing content uniformity specifications. This failure means the tablets may contain a strength that is more or less than what is labeled on the bottle.

The affected product was distributed nationwide in the United States and Puerto Rico. Patients and healthcare providers should stop using the recalled product and contact their healthcare provider for guidance on alternative treatment options. Consumers should check their medication bottles for the specific lot numbers and expiration dates listed in the recall notice.

The recalled product

Product
Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1/2 grain (30 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-155-04.
Manufacturer
Westminster Pharmaceuticals LLC
Category
Drug — Prescription Medication
Hazard

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (8)

  • Lot #: 15517VP01
  • 15517VP02
  • 15517VP03
  • Exp 8/31/2019
  • 15518001
  • Exp 12/31/2019
  • 15518002
  • Exp 3/31/2020.

Distribution

Distributed nationwide across the United States.

The notice also names 1 state specifically:

Part of a larger recall action

This product is one of 5 recalled by Westminster Pharmaceuticals LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 5 products in this recall →

Related recalls

Same manufacturer · Westminster Pharmaceuticals LLC

See all →

Same hazard · adulterated ingredient

See all →

Similar recalls